



ALTERNATIVE TO PTO/SB/08A/B (09/06)

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete if Known
Application Number				10/600,802
Filing Date				June 19, 2003
First Named Inventor				Jennie P. MATHER
Art Unit				1642
Examiner Name				M. Davis
Sheet	1	of	1	Attorney Docket Number 415072002500

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)				
/T.D.	1.	WO-01/14557-A1	03-01-2001	Dana-Farber Cancer Institute, Inc. et al.		
/T.D.	2.	WO-01/89567-A1	11-29-2001	IDEC Pharmaceuticals Corporation		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/T.D.	3.	Supplementary Partial European Search Report mailed March 12, 2007, for EP Application No. 03761281.9 filed June 19, 2003, five pages.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature pa- 1164051	/Minh Tam Davis/ (09/10/2007)	Date Considered
-----------------------------------	-------------------------------	-----------------



Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number 415072002500

**Complete if Known**

Application Number	10/600,802
Filing Date	June 19, 2003
First Named Inventor	Jennie P. MATHER
Art Unit	1641
Examiner Name	M. Davis

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
/T.D./	1.	WO-2004/001381-A2	12-31-2003	Raven biotechnologies, inc.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/T.D./	2.	Chapoval, A.I. et al. (March 2001). "B7-H3: A Costimulatory Molecule for T cell Activation and IFN-γ Production," <i>Nature Immunology</i> 2(3):269-274.	
/T.D./	3.	International Search Report for PCT/US03/19819 filed June 19, 2003, mailed May 19, 2005, five pages.	

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature pa- 982488	/Minh Tam Davis/ (09/10/2007)	Date Considered
----------------------------------	-------------------------------	-----------------



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION  
*(Use several sheets if necessary)*

Docket Number 415072002500 Application Number 10/600,802

Applicant	Jennie P. MATHER et al.
Filing Date June 19, 2003	Group Art Unit 1641
Mailing Date October 1, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
/T.D./	1.	06/30/1987	4,676,980	Segal et al.			
	2.	03/28/1989	4,816,567	Cabilly et al.			
	3.	09/03/1996	5,552,391	Coutts et al.			
	4.	10/15/1996	5,565,332	Hoogenboom et al.			
	5.	12/03/1996	5,580,717	Dower et al.			
	6.	08/12/1997	5,656,444	Webb et al.			
	7.	03/31/1998	5,733,743	Johnson et al.			
	8.	09/15/1998	5,807,715	Morrison et al.			
	9.	02/02/1999	5,866,692	Shitara et al.			
	10.	12/07/1999	5,997,867	Waldmann et al.			
	11.	04/25/2000	6,054,297	Carter et al.			
	12.	04/25/2000	6,054,561	Ring			
	13.	01/30/2001	6,180,377	Morgan et al.			
	14.	07/24/2001	6,265,150	Terstappen et al.			
	15.	12/18/2001	6,331,415	Cabilly et al.			
	16.	07/09/2002	6,416,999	Li et al.			
	17.	08/20/2002	6,436,704	Roberts et al.			
▼	18.	08/27/2002	6,441,163	Chari et al.			


FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
/T.D./	19.	12/23/1992	EP 0 519 596	Europe			
	20.	03/15/2001	WO 01/018021	WIPO			
▼	21.	10/18/2001	WO 01/77303	WIPO			
▼	22.	01/31/2002	WO 02/08279	WIPO			

EXAMINER: /Minh Tam Davis/ (09/10/2007)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Docket Number 415072002500	Application Number 10/600,802
				Applicant	Jennie P. MATHER et al.
				Filing Date June 19, 2003	Group Art Unit 1641
				Mailing Date October 1, 2003	

	23.	02/07/2002	WO 02/10187	WIPO			
	24.	08/21/2003	WO 03/068938	WIPO			

		OTHER DOCUMENTS			<i>(including author, title, Date, Pertinent Pages, Etc.)</i>		
Examiner Initials	Ref. No.	Title					
/T.D./	25.	Arrufo, A. and Seed, B. (1987). "Molecular Cloning of a CD28 cDNA by a High Efficiency COS Cell Expression System," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 84:8573-8577.					
	26.	Brown, B.A. et al. (1987). "Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody," <i>Cancer Res.</i> 47:3577-3583.					
	27.	Carter, P. et al. (1992). "Humanization of an Anti-p185 <sup>HER2</sup> Antibody for Human Cancer Therapy," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:4285-4289.					
	28.	Clouser, K.R. et al. (1999). "Role of Accurate Mass Measurement ( $\pm$ 10 ppm) in Protein Identification Strategies Employing MS or MS/MS and Database Searching," <i>Analytical Chemistry</i> 71(14):2871-2882.					
	29.	Co, M.S. et al. (1991). "Humanized Antibodies for Antiviral Therapy," <i>Proc. Natl Acad Sci. U.S.A.</i> 88:2869-2873.					
	30.	Co, M.S. et al. (1992). "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," <i>J. Immunol.</i> 148(4):1149-1154.					
	31.	Daugherty, B.L. et al. (1991). "Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19(9):2471-2476.					
	32.	Dillman, R.O. et al. (1988). "Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug," <i>Cancer Res.</i> 48:6097-6102.					
	33.	Gennaro, A.R. ed. (2000). <i>Remington: The Science and Practice of Pharmacy</i> Twentieth Edition, Lippincott Williams & Wilkins: Philadelphia, PA pp. xiv-xv (Table of Contents Only.)					
	34.	Gharahdaghi, F. et al. (1999). "Mass Spectrometric Identification of Proteins From Silver-Stained Polyacrylamide Gel: A Method For The Removal of Silver Ions to Enhance Sensitivity," <i>Electrophoresis</i> 20:601-605.					
	35.	Goldenberg, D.M. ed. (1995). <i>Cancer Therapy With Radiolabeled Antibodies</i> CRC Press: Boca Raton, FL, four pages (Table of Contents Only.)					
	36.	Gorman, S.D. et al. (1991). "Reshaping a Therapeutic CD4 Antibody," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88:4181-4185.					
▼	37.	Jones, P.T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse," <i>Nature</i> 321:522-525.					

EXAMINER: /Minh Tam Davis/ (09/10/2007)	DATE CONSIDERED:
---	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number 415072002500	Application Number 10/600,802
		Applicant	Jennie P. MATHER et al.
		Filing Date June 19, 2003	Group Art Unit 1641
		Mailing Date October 1, 2003	

/T.D./	38.	Kettleborough, C.A. et al. (1991). "Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation," <i>Protein Engineering</i> 4:(7)773-783.
	39.	Kohler, G. and Milstein, C. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> 256:495-497.
	40.	LoBuglio, A.F. et al. (1989). "Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 86:4220-4224.
	41.	Lonberg, N. and Huszar, D. (1995). "Human Antibodies From Transgenic Mice," <i>Int. Rev. Immunol.</i> 13:65-93.
	42.	Maeda, H. et al. (1991). "Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity," <i>Human Antibodies Hybridoma</i> 2:124-134.
	43.	Mahato, R.I. et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm. Res.</i> 14(7):853-859.
	44.	Mangham, D.C. and Isaacson, P.G. (1999). "A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA)," <i>Histopathology</i> 35(2):129-133.
	45.	Peeters, K. et al. (2001). "Production of Antibodies and Antibody Fragments in Plants," <i>Vaccine</i> 19:2756-2761.
	46.	Pollock, D.P. et al. (1999). "Transgenic Milk as a Method for the Production of Recombinant Antibodies," <i>J. Immunol. Methods</i> 231:147-157.
	47.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," <i>Nature</i> 332:323-327.
	48.	Sato, K. et al. (1993). "Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth," <i>Cancer Res.</i> 53:851-856.
	49.	Shaw, D.R. et al. (1987). "Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen," <i>J. Immunol.</i> 138(12):4534-4538.
	50.	Shen, W-C. and Ryser, H. J-P. (1981). "CIS-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of ph-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate," <i>Biochem. Biophys. Res. Commun.</i> 102(3):1048-1054.
	51.	Stephan, J-P. et al. (1999). "Distribution and Function of the Adhesion Molecule BEN During Rat Development," <i>Dev. Biol.</i> 212:264-277.
	52.	Stephan, J-P. et al. (1999). "Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation," <i>Endocrinology</i> . 140(12):5841-5854.
▼	53.	Sun, M. et al. (2000). "Characterization of Mouse and Human B7-H3 Genes," <i>J. Immunol.</i> 168:6294-6297. 2002

EXAMINER: /Minh Tam Davis/ (09/10/2007)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>		Docket Number 415072002500	Application Number 10/600,802
		Applicant	Jennie P. MATHER et al.
		Filing Date June 19, 2003	Group Art Unit 1641
		Mailing Date October 1, 2003	

/T.D./	54.	Tempest, P.R. et al. (1991). "Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection <i>in Vivo</i> ," <i>Bio/Technology</i> 9:266-271.
	55.	Trouet, A. et al. (1982). "A Covalent Linkage Between Daunorubicin and Proteins that is Stable in Serum and Reversible by Lysosomal Hydrolases, As Required For a Lysosomotropic Drug-Carrier Conjugate: <i>In vitro</i> and <i>in vivo</i> Studies," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 79:626-629.
	56.	Verhoeven, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <i>Science</i> 239:1534-1536.
	57.	Weiner, L.M. et al. (2001). "Therapeutic Monoclonal Antibodies: General Principles," Section 5, Chapter 20 <i>In Cancer: Principles and Practice of Oncology</i> Sixth Edition Lippincott Williams & Wilkins: Philadelphia, PA pp. 495-508.
	58.	Wheatley, S.P. and Wang, Y-L. (1998). "Indirect Immunofluorescence Microscopy in Cultured Cells," Chapter 18 <i>In Methods In Cell Biology</i> Mather, J.P. and Barnes, D. eds. Academic Press Vol. 57, pp. 313-332.
	59.	Winter, G. and Milstein, C. (1991). "Man-Made Antibodies," <i>Nature</i> 349:293-299.
	60.	Winter, G. et al. (1994). "Making Antibodies by Phage Display Technology," <i>Annu. Rev. Immunol.</i> 12:433-455.
	61.	Woodruff, T.K. (1998). "Cellular Localization of mRNA and Protein: <i>In Situ</i> Hybridization Histochemistry and <i>in Situ</i> Ligand Binding," Chapter 19 <i>In Methods In Cell Biology</i> Mather, J.P. and Barnes, D. eds. Academic Press Vol. 57, pp. 333-351.
↓	62.	Yang, H.M. and Reisfeld, R.A. (1988). "Pharmacokinetics and Mechanism of Action of a Doxorubicin-Monoclonal Antibody 9.2.27 Conjugate Directed to a Human Melanoma Proteoglycan," <i>J. Natl. Canc. Inst.</i> 80:1154-1159.

EXAMINER: /Minh Tam Davis/ (09/10/2007)	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	